Antisense modulation of IL-1 receptor-associated kinase-1 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsBrenda F. Baker, Susan M. Freier, Kenneth W. Dobie
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of IL-1 receptor-associated kinase-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding IL-1 receptor-associated kinase-1. Methods of using these compounds for modulation of IL-1 receptor-associated kinase-1 expression and for treatment of diseases associated with expression of IL-1 receptor-associated kinase-1 are provided.
Claims20
A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding IL-1 receptor-associated kinase-1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding IL-1 receptor-associated kinase-1 and inhibits the expression of IL-1 receptor-associated kinase-1.
A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding IL-1 receptor-associated kinase-1.
Dependencies are inferred from the claim text.